Rossmax International (4121) reported revenue of NT$342.3 million for Oct 2026, +10.2% year on year and +4.2% from the previous month. Revenue for Jan–Oct 2026 was NT$3.21 billion (+1.7% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 28 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$342.3 million | +10.2% | +4.2% |
| Sep 2026 | NT$328.6 million | +9.2% | -1.1% |
| Aug 2026 | NT$332.2 million | +4.0% | +2.4% |
| Jul 2026 | NT$324.5 million | +1.2% | -1.0% |
| Jun 2026 | NT$327.9 million | +2.1% | +3.2% |
| May 2026 | NT$317.9 million | -3.5% | +5.6% |
| Apr 2026 | NT$300.9 million | -9.2% | -4.9% |
| Mar 2026 | NT$316.4 million | +2.2% | +6.1% |
| Feb 2026 | NT$298.1 million | +4.6% | -7.9% |
| Jan 2026 | NT$323.8 million | -2.2% | +5.4% |
| Dec 2025 | NT$307.1 million | -10.7% | -7.8% |
| Nov 2025 | NT$333.2 million | +1.6% | +7.2% |
| Oct 2025 | NT$310.7 million | +4.3% | +3.2% |
| Sep 2025 | NT$300.9 million | -4.7% | -5.8% |
| Aug 2025 | NT$319.4 million | -2.4% | -0.4% |
| Jul 2025 | NT$320.8 million | -3.1% | -0.1% |
| Jun 2025 | NT$321.1 million | +2.2% | -2.5% |
| May 2025 | NT$329.4 million | +5.6% | -0.6% |
| Apr 2025 | NT$331.3 million | -0.5% | +7.0% |
| Mar 2025 | NT$309.7 million | +1.5% | +8.6% |
| Feb 2025 | NT$285.1 million | -8.5% | -13.8% |
| Jan 2025 | NT$331 million | -0.3% | -3.8% |
| Dec 2024 | NT$344 million | +0.6% | +4.9% |
| Nov 2024 | NT$327.9 million | +5.5% | +10.1% |
| Oct 2024 | NT$297.8 million | -4.2% | -5.7% |
Jan–Oct 2026 cumulative: NT$3.21 billion (+1.7% YoY)
Other Biotech & Medical companies
Compare with peers: Rossmax International vs PEC / Rossmax International vs Lotus Pharm / Rossmax International vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16